5.02
-0.09(-1.76%)
Currency In USD
Address
85 Bolton Street
Boston, MA 02140
United States of America
Phone
617 500 8864
Sector
Healthcare
Industry
Biotechnology
Employees
106
First IPO Date
October 29, 2021
| Name | Title | Pay | Year Born |
| Elisabet de los Pinos | Founder, Chief Executive Officer, President & Director | 948,209 | 1974 |
| Conor Kilroy | Chief Legal Officer & Secretary | 611,162 | 1982 |
| Jill Hopkins | Chief Medical Officer & President of Research and Development | 761,250 | 1965 |
| Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology | 0 | N/A |
| Mark Plavsic | Chief Technology Officer | 0 | 1961 |
| Richard Mountfield | Senior Vice President of Regulatory Affairs & Quality | 0 | N/A |
| Sabine Brookman-May | Senior VP & Therapeutic Area Head of Urologic Oncology | 0 | N/A |
| Anthony S. Gibney | Chief Financial & Business Officer | 0 | 1971 |
| Patrick Nealon | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Amy Elazzouzi | Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer | 0 | 1974 |
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.